Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bayer AG is conducting a study titled ‘Long-term Special Drug Use Investigation of Molidustat for Patients With Renal Anemia’ to assess the long-term safety and effectiveness of Molidustat in Japanese men and women suffering from renal anemia. This condition arises when kidneys fail to produce enough of a hormone crucial for red blood cell production. The study aims to evaluate the incidence of adverse events observed in earlier trials and the potential increase in red blood cell count following Molidustat treatment.
The intervention being tested is Molidustat, commercially known as Musredo or BAY85-3934, which is an oral medication administered at the discretion of investigators. It is designed to treat renal anemia by potentially increasing red blood cell production.
This observational study follows a cohort model with a prospective time perspective. Participants’ health data will be collected from medical records and regular check-ups over two years, with the primary purpose of evaluating real-world safety and effectiveness.
The study began on August 6, 2021, with its primary completion and estimated final completion yet to be announced. The last update was submitted on June 22, 2025, indicating ongoing data collection and analysis.
For investors, the study’s progress could impact Bayer’s stock performance, especially if Molidustat proves effective and safe, potentially strengthening Bayer’s position in the renal anemia treatment market. Competitors in the pharmaceutical industry may also be monitoring these developments closely.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.